SCHEMBL3474472

SCHEMBL3474472

FC(F)c1cnccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.41
CDC25B P30305 1/20 0.38
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ROCK2 O75116 1/20 0.34
ROCK1 Q13464 1/20 0.34
GRIN2B Q13224 3/20 0.32
RXRA P19793 2/20 0.32
GRIN1 Q05586 2/20 0.32
KCNH2 Q12809 1/20 0.32
CYP19A1 P11511 3/20 0.32
CYP2A6 P11509 1/20 0.31
TDO2 P48775 1/20 0.31
RPS6KA3 P51812 1/20 0.31
NFATC1 O95644 1/20 0.31
GSK3B P49841 1/20 0.31
DYRK1A Q13627 1/20 0.31
IMPDH2 P12268 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29544825 1.00 GAA (0.41) GAACDC25BHPGDHSD17B10ROCK2
SCHEMBL21745752 0.82 GAA (0.46) GAACDC25BHPGDHSD17B10ROCK2
SCHEMBL31651702 0.79 GAA (0.43) GAACDC25BHPGDHSD17B10ROCK2
SCHEMBL5700259 0.79 GAA (0.43) GAACDC25BHPGDHSD17B10ROCK2
SCHEMBL23489766 0.74 GAA (0.39) GAACDC25BHPGDHSD17B10ROCK2
SCHEMBL17000182 0.74 GAA (0.39) GAACDC25BHPGDHSD17B10ROCK2
SCHEMBL17318479 0.74 GAA (0.39) GAACDC25BHPGDHSD17B10ROCK2
SCHEMBL31473883 0.74 GAA (0.39) GAACDC25BHPGDHSD17B10ROCK2
SCHEMBL31358476 0.74 GAA (0.35) GAACDC25BHPGDHSD17B10ROCK2
SCHEMBL14907178 0.73 SIRT3 (0.39) GAACYP2A6TDO2RPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105121418-A Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection GILEAD SCIENCES INC 2015-12-02 CN disclosed
US-7754188-B2 Radiolabeled cannabinoid-1 receptor modulators MERCK SHARP & DOHME CORP. (US) 2010-07-13 US disclosed
US-20080076805-A1 Acyclic Hydrazides as Cannabinoid Receptor Modulators MERCK SHARP & DOHME CORP. 2008-03-27 US disclosed
EP-1641493-A4 RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS MERCK & CO INC (US) 2007-10-31 EP disclosed
CN-101048368-A Acyclic hydrazides as cannabinoid receptor modulators MERCK & CO INC (US) 2007-10-03 CN disclosed
EP-1807388-A2 ACYCLIC HYDRAZIDES AS CANNABINOID RECEPTOR MODULATORS Merck & Co., Inc. (US) 2007-07-18 EP disclosed
US-20060115425-A1 Substituted amides MERCK SHARP & DOHME CORP. 2006-06-01 US disclosed
WO-2006041797-A2 ACYCLIC HYDRAZIDES AS CANNABINOID RECEPTOR MODULATORS MERCK & CO., INC. (US) 2006-04-20 WO disclosed
EP-1641493-A1 RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS Merck & Co., Inc. (US) 2006-04-05 EP disclosed
WO-2005009479-A1 RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS MERCK & CO., INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076805-A1 Acyclic Hydrazides as Cannabinoid Receptor Modulators CNR1, CNR2, FAAH GAA 1097/4885CDC25B 3387/4885HPGD 985/4885
US-20060115425-A1 Substituted amides CNR1, CNR2, FAAH GAA 3104/4885CDC25B 3253/4885HPGD 1285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.